Fc-mediated ADCC: trastuzumab binds HER2 on target cells and engages Fcγ receptor–bearing effector cells (e.g., NK cells/macrophages) to lyse the bound cell; it also blocks HER2 signaling and promotes downregulation/apoptosis.